BSE Live
Feb 05, 16:01Prev. Close
1958.05
Open Price
1967.25
Bid Price (Qty.)
1931.10 (3)
Offer Price (Qty.)
1972.40 (54)
NSE Live
Feb 05, 15:50Prev. Close
1959.30
Open Price
1955.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1969.30 (18)
| Profit & Loss account of Glenmark Pharma (in Rs. Cr.) | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | ||
| INCOME | |||
| Revenue From Operations [Gross] | 538.13 | 381.42 | |
| Less: Excise/Sevice Tax/Other Levies | 42.69 | 30.84 | |
| Revenue From Operations [Net] | 495.45 | 350.58 | |
| Total Operating Revenues | 495.45 | 350.58 | |
| Other Income | 3.78 | 2.61 | |
| Total Revenue | 499.23 | 353.19 | |
| EXPENSES | |||
| Cost Of Materials Consumed | 156.71 | 102.20 | |
| Purchase Of Stock-In Trade | 32.28 | 28.60 | |
| Operating And Direct Expenses | 16.61 | 9.98 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -23.76 | -21.88 | |
| Employee Benefit Expenses | 49.49 | 38.83 | |
| Finance Costs | 16.73 | 10.06 | |
| Depreciation And Amortisation Expenses | 14.98 | 10.89 | |
| Other Expenses | 149.25 | 121.97 | |
| Total Expenses | 412.29 | 300.65 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 86.94 | 52.54 | |
| Exceptional Items | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 86.94 | 52.54 | |
| Tax Expenses-Continued Operations | |||
| Current Tax | 14.33 | 9.00 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | |
| Deferred Tax | 9.13 | 1.51 | |
| Tax For Earlier Years | 0.00 | 0.00 | |
| Total Tax Expenses | 23.45 | 10.54 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 63.48 | 42.00 | |
| Profit/Loss From Continuing Operations | 63.48 | 42.00 | |
| Profit/Loss For The Period | 63.48 | 42.00 | |
| OTHER ADDITIONAL INFORMATION | |||
| EARNINGS PER SHARE | |||
| Basic EPS (Rs.) | 5.35 | 7.09 | |
| Diluted EPS (Rs.) | 5.35 | 7.09 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | |||
| Imported Raw Materials | 36.10 | 28.25 | |
| Indigenous Raw Materials | 108.70 | 68.36 | |
| STORES, SPARES AND LOOSE TOOLS | |||
| Imported Stores And Spares | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 4.51 | 2.46 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | |||
| Equity Share Dividend | 8.30 | 7.70 | |
| Tax On Dividend | 1.26 | 1.12 | |
| Equity Dividend Rate (%) | 35.00 | 65.00 |
04.02.2026
03.02.2026
Glenmark Consolidated December 2025 Net Sales at Rs 3,900.62 crore, up 15.15% Y-o-Y
03.02.2026
Glenmark Standalone December 2025 Net Sales at Rs 2,359.94 crore, up 4.83% Y-o-Y
05.01.2026
Chartist Talk: Avoid Vodafone Idea; Escorts Kubota, Glenmark set for breakout, says Milan Vaishnav
03.02.2026
Glenmark Consolidated December 2025 Net Sales at Rs 3,900.62 crore, up 15.15% Y-o-Y
03.02.2026
Glenmark Standalone December 2025 Net Sales at Rs 2,359.94 crore, up 4.83% Y-o-Y
04.12.2025
Glenmark Consolidated September 2025 Net Sales at Rs 6,046.87 crore, up 76.1% Y-o-Y
24.11.2025
Glenmark Standalone September 2025 Net Sales at Rs 1,538.66 crore, down 41.63% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015